Fig. 2

Induction of prosurvival PERK signaling by G9a inhibition in KG1 LSC-like cells. a, Expression of PERK pathway proteins, analyzed by western blotting, in cells treated with various concentrations of BIX-01294 for 24 h. b, Protein expression, analyzed by western blotting with the indicated antibodies, in cells transfected with G9a-targeting or control siRNA. c, Flow cytometric analysis of the apoptotic fraction of cells treated with various concentrations of BIX-01294 in the absence or presence of the PERK inhibitor GSK2606414 (20 μmol/L) for 48 h. d, Apoptosis levels, determined by flow cytometry, in cells transfected with PERK-targeting or control siRNA and treated with various concentrations of BIX-01294 for 48 h. e, Protein expression, analyzed by western blotting with the indicated antibodies, in PERK/control siRNA-transfected cells after treatment with 15 μmol/L BIX-01294 for 48 h. f, Protein expression, analyzed by western blotting with the indicated antibodies, in cells treated with BIX-01294 (10 μmol/L) in the absence or presence of GSK2606414 (20 μmol/L) for 48 h. g, Apoptosis levels, determined by flow cytometry, in cells pretreated or not with Z-VAD-FMK (20 mmol/L) for 1 h and then treated with BIX-01294 (10 μmol/L) and GSK2606414 (20 μmol/L) for 48 h. h, Apoptosis levels, determined by flow cytometry, in cells transfected with G9a-targeting or control siRNA and incubated with GSK2606414 (10 μmol/L) for 48 h